The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc’s BRTX metabolic ThermoStem program.
The notice of allowance was issued on February 6, 2023.
What Happened: Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes derived from human brown adipose-derived stem cells.
Related: EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome.
The therapeutic combination of scaffolds as a delivery system and brown adipose-derived stem cells provides the ability to deliver metabolically active cells.
Why It Matters: The therapeutic benefits of using brown adipose have been demonstrated in various models. Certain companies that use encapsulation technology coupled with cells have shown promising clinical results in treating type 1 diabetes in their Phase 1/2 clinical trials.
“We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes,” said Lance Alstodt, the company’s CEO.
Price Action: BRTX shares are up 2.31% at $3.08 premarket on the last check Wednesday.
